December 2, 2024- SUDO-550 is a potential best-in-class, orally administered, brain-penetrant TYK2 inhibitor being developed for the treatment of neuroinflammatory diseases. -…
November 19, 2024PK data analysis in dose-escalation phase indicated exposures of QRL-201 met or exceeded the targeted therapeutic range prompting advancement to…
October 7, 2024-Development Candidate NDC-0524 is a First-in-Class, Humanized Therapeutic Antibody with High Affinity and Selectivity for Nitrated -Synuclein, which is Rapidly Being…
October 2, 2024Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop…- September 10, 2024QRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients Completed Phase 1…
September 4, 2024Dr Paulo Fontoura brings 20 years’ experience of working in the pharma industry, with the most recent 16 years focusing…
August 2, 2024SAN FRANCISCO, July 30, 2024 (GLOBE NEWSWIRE) -- Montara Therapeutics, Inc. (‘Montara’), a therapeutics company aiming to revolutionize the discovery…- May 30, 2024Newly established SAB of prominent geneticists, biologists and Huntington’s disease specialists’ marks pivotal step in accelerating progress of lead programme…
May 23, 2024Cambridge, UK, May 23, 2024 – Amphista Therapeutics (“Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces…
May 21, 2024Designation Supports Accelerated Drug Development for PSP TPN-101 is the First PSP Treatment to Reduce NfL and IL-6 Levels, Key Biomarkers…
May 9, 2024Sacramento, May 8, 2024 (GLOBE NEWSWIRE) — Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven…
May 2, 2024BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system…- April 25, 2024Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others…
- April 24, 2024Ms. Chhabra Karson brings highly successful 20-year track record in industry leadership roles Cambridge, UK, April 24 2024: Harness Therapeutics, a…
April 15, 2024LONDON — APRIL 15, 2024 — AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines…- March 14, 2024NIHR-Funded Study Represents the Largest of its Kind Conducted to Date in Alzheimer's Dementia. Cumulus Neuroscience today announced the enrollment…
March 11, 2024-Nitrase’s first-in-class antibody found to significantly delay progression of Parkinson’s disease in preclinical models by blocking the propagation of pathogenic…- February 13, 2024CARMEL, IN - Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors,…
- February 13, 2024TPN-101 is the first PSP treatment to reduce NfL and IL-6 levels, key biomarkers of neurodegeneration and neuroinflammation in PSP…
- January 24, 2024Cambridge, UK, January 24th, 2024 – Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD)…
- November 28, 2023Cambridge, UK, 28th November 2023: Harness Therapeutics (‘Harness’, previously Transine Therapeutics), a biotechnology company focused on physiological protein upregulation to…
November 21, 2023Dementia Discovery Fund Announces the Acquisition of Caraway Therapeutics by Merck This transaction highlights DDF’s attractive strategy of investing in…- November 14, 202324-Week data show TPN-101 is the first treatment for PSP to reduce NfL levels, a keybiomarker of neurodegeneration in tauopathies…
- November 6, 2023• AVB-101 is an investigational gene therapy delivered as a one-time infusion directly to the brain, enabling distribution to brain…
- October 18, 2023BELFAST, Northern Ireland and CAMBRIDGE, Mass., October 18, 2023 / -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused…
- October 10, 2023• AVB-101 is an investigational gene therapy designed to halt disease progression by delivering a functional copy of the GRN…
- October 9, 2023London UK, XXXX– AstronauTx Ltd. (“AstronauTx”), a biotech company developing novel treatments for Alzheimer’s disease and other neurodegenerative disorders today…
- October 8, 2023AstronauTx’s financing is step towards helping millions of people suffering from disease View the article
September 29, 2023DDF Understanding Dementia- August 28, 2023Boston, MA – August 28, 2023 – Cerevance, a private, clinical-stage drug discovery and development company focused on advancing novel, precision…
- July 25, 2023The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions…
- July 6, 2023Dementia, the looming health crisis of our time, has long lacked effective treatments. But now, recent drug breakthroughs and the…
- June 28, 2023Boston, MA (US) and London (UK) –June 28th 2023. The Dementia Discovery Fund (DDF), the world’s largest family of specialized venture capital…
- May 31, 2023Oxford and Cambridge Among Sites Participating in CNS-101 Validation Study BELFAST, Northern Ireland and CAMBRIDGE, Mass., May 31, 2023 /PRNewswire/…
May 31, 2023Round led by the DDF (through DDF-2) and co-led by UTEC (University of Tokyo Edge Capital Partners) and founding investor…- May 19, 2023AARP-backed research into ALS, Alzheimer’s could lead to dementia drugs View the article
- May 15, 2023SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company focused on developing fibrin-targeted therapies to treat inflammatory neurodegenerative and…
- April 27, 2023Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. SOUTH SAN FRANCISCO,…
- April 18, 2023BRISBANE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build…
- April 6, 2023First patient dosed in Canada in Phase 1 ANQUR study – the first-ever clinical trial to evaluate a therapy that…
- March 9, 2023QurAlis picked up $88 million for two Phase I studies, hoping to ride regulatory waves driven by the recent FDA…
- March 9, 2023EQT Life Sciences, Droia Ventures, and Sanofi Ventures led the round Financing supports clinical activities for Company’s two lead programs…
- February 23, 2023• Subpial delivery technology has the potential to offer precise, efficient, and safer delivery of gene therapies for neurological diseases with…
- February 20, 2023Some of the world’s biggest health challenges do not lend themselves to conventional investment “Dementia is a massive, massive swing…
- February 13, 2023Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform CVN424 for Parkinson’s disease will advance to Phase…
- January 5, 2023QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration CAMBRIDGE, Mass., January 5, 2023 – QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision…
- December 13, 2022Cambridge, UK – December 13, 2022 – Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today…
- December 8, 2022First ever study to evaluate a therapy that rescues STATHMIN-2 expression in ALS patients expected to initiate in Canada in…
- October 31, 2022Company discovered selective nitration and regulation of tumor-intrinsic and immuno-oncology targets by several of its proprietary nitrases BRISBANE, Calif., Oct.…
- September 29, 2022Eisai and Biogen report positive results from lecanemab Phase 3 study in Alzheimer’s disease with a statistically significant slowdown in…
- September 21, 2022Tapping AliveCor Senior Executive, Cumulus Signals Progression To A Global Healthcare Company; Dr. Bhatti To Lead Expansion of AI-Based Digital…
- September 12, 2022• Award reinforces AviadoBio’s position as one of the most promising early-stage biotech companies in the gene therapy industry London,…
September 12, 2022Searching for protective antibodies in ‘resilient’ people may provide a new approach for discovering drug targets. View the article- September 7, 2022BRISBANE, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build…
- August 9, 2022Pharma pays $25M up front to use target discovery platform as privately-held Cerevance plots path forward for wholly-owned clinical program…
- August 9, 2022Cerevance to concurrently out-license one discovery-stage program Boston, MA – AUGUST 9, 2022 – Cerevance, a private, clinical-stage drug discovery and…
- July 6, 2022SAN FRANCISCO, July 06, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its unique NITROME platform to…
June 21, 2022Industry veteran brings proven track record in building successful businesses and leading high-performance teams across large pharmaceutical, biotech, and specialty…- May 31, 2022Cambridge, UK, 31 May 2022: Transine Therapeutics (‘Transine’), a biotechnology company developing a novel class of therapeutic RNAs based on…
- April 27, 2022• FDA and EC decisions reinforce severity of unmet medical need with this rare, aggressive form of dementia • AviadoBio…
- April 19, 2022Craig Thompson Appointed Chief Executive Officer Founder Brad Margus Assumes Role of Executive Chairman of the Board Boston, MA – April…
- April 5, 2022-- Grant to fund exploration of potential new biomarker for Parkinson’s disease -- BRISBANE, Calif., April 05, 2022 (GLOBE NEWSWIRE)…
- March 31, 2022Demonstrates the Power of Cerevance’s Deep Understanding of Specific Human Brain Cell Types Boston, MA – March 31, 2022 – Cerevance,…
- March 20, 2022The coronavirus gave us a blueprint for tackling a health crisis: cut red tape and fund more research — but…
- March 19, 2022By targeting the DNA damage repair pathway, the U.K. biotech hopes to stop the formation of mutated HTT, not clean…
- March 18, 2022-Company Identifies Potential New Biomarker And Diagnostic For Parkinson’s Disease- SAN FRANCISCO, March 18, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc.…
- March 2, 2022– Esteemed Harvard Medical School Professor Emeritus and HHMI Investigator, Dr. David Clapham, brings world class expertise on ciliary ion…
- January 25, 2022Dr. Ivarsson is currently Chief Development Officer at Moderna and led clinical trials of the company’s Covid-19 vaccineCambridge, UK –…
- December 1, 2021London, UK, December 2, 2021 — AviadoBio Ltd, a pioneering gene therapy company focused on developing and delivering transformative medicines…
- November 23, 2021- Company targets DNA mismatch repair pathways to slow neurodegeneration in Huntington's Disease and other triplet repeat disorders - LoQus23's…
- November 2, 2021--Founder Irene Griswold-Prenner, Ph.D., Focuses on Role as Chief Scientific Officer—San Francisco, CA – November 2, 2021 – Nitrase Therapeutics, Inc.…
- September 22, 2021If we want to stop Alzheimer’s disease, one of the biggest things we need to develop is a reliable, affordable,…
- September 14, 2021QRL-201 is a first-in-class molecule that rescues STATHMIN-2 loss of function in motor neuron disease models in the presence of…
- September 14, 2021BELFAST, Northern Ireland, Sept. 14, 2021 /PRNewswire/ -- Cumulus Neuroscience (Cumulus, The Company), a leading global innovator providing real-world clinical…
- July 5, 2021Dr Thirkettle is a seasoned life sciences executive with deep experience and a proven track record in building successful novel…
July 2, 2021GlaxoSmithKline plc (LSE/NYSE: GSK) and Alector (Nasdaq: ALEC), today announced a strategic global collaboration for the development and commercialisation of…- June 24, 2021Three years later, Dementia Discovery Fund now backs 18 companies seeking treatments View the article
- June 22, 2021Industry Veteran Brings Experience and Proven Track Record of Success Plans for Management Team Expansion and Global Reach Through Newly…
- June 12, 2021We are delighted to share the news that Kate Bingham, Managing Partner in the SV Biotech team, has been recognised in…
- June 11, 2021Biocentury article
- June 9, 2021Boston, MA (US) and London (UK) – June 9, 2021. The Dementia Discovery Fund (DDF) is pleased to announce that Caraway Therapeutics,…
- June 9, 2021CAMBRIDGE, MA – June 9, 2021 – Caraway Therapeutics today announced an exclusive, collaboration and option agreement with AbbVie (NYSE: ABBV) to…
- June 7, 2021Boston, MA (US) and London (UK) – June 7th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in,…
- June 2, 2021New Company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression Cambridge, UK, 2nd June 2021: Transine Therapeutics…
- May 26, 2021Vikas Sharma, Ph.D., Shirley Lasch, and Tim O’Brien join team dedicated to developing new treatments for ALS and other genetically…
- May 10, 2021Strengthens investor syndicate with SV's Impact Medicine Fund, MRL Ventures and Sanofi Ventures joining to accelerate development of disease-modifying drugs…
- May 5, 2021Boston, MA (US) and London (UK) – May 5th, 2021. The Dementia Discovery Fund (DDF), the venture capital fund investing in, and…
- May 4, 2021Belfast, UK - 4 May 2021. Cumulus Neuroscience (Cumulus, The Company), formerly known as BrainWaveBank, announces a £6m financing round led…
- April 15, 2021Funding round led by RA Capital Management with Lightstone Ventures and DHVC follows a Seed round led by SV Health…
- April 7, 2021World-recognized experts Dr. Lynne Hughes and Dr. James Summers appointed as Venture Partners Boston, MA (US) and London (UK) – April…
- March 17, 2021Cambridge, MA, 17, March 2021 Amathus Therapeutics announced today a strategic collaboration with Merck, known as MSD outside the United…
- March 16, 2021March 16, 2021 05:00 AM Eastern Daylight Time LONDON--(BUSINESS WIRE)--Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat…
- February 2, 2021CAMBRIDGE, Mass., February 2, 2021— QurAlis Corporation, a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS)…
January 6, 2021January 06, 2021 06:30 AM Eastern Standard Time DURHAM, N.C.--(BUSINESS WIRE)--Ribometrix, Inc., today announced a strategic collaboration with Genentech, a…- November 18, 2020CAMBRIDGE, Mass.--(BUSINESS WIRE)--Caraway Therapeutics today announced that the Company has been awarded a second research grant from The Michael J. Fox…
- November 16, 2020Positive results with biomarker of cerebral cortical dysfunction raises hope for treatment of cognitive impairment associated with schizophrenia Boston, MA –…
- November 12, 2020Nitrome SAB composed of esteemed experts and key scientific thought leaders in neurobiology and drug development SAN FRANCISCO, Nov. 12,…
- September 28, 2020According to Fierce Biotech, what makes QurAlis fierce: There are currently four drugs approved by the U.S. FDA to treat ALS:…
- July 22, 2020The additional proceeds will aid in the development of the company’s NETSseq platform which it is using to discover entirely…
- July 1, 2020QurAlis to in-license lead excitotoxicity targeted ALS therapeutic candidates from LillyCambridge, MA, July 01, 2020 — QurAlis Corporation, a biotech company focused…
- June 2, 2020MANCHESTER, England, June 2, 2020 /PRNewswire/ -- The therapeutics biotech AstronauTx announces a partnership with Concept Life Sciences, Contract Research…
- May 13, 2020Funding led by Polaris Partners, Mission BioCapital, INKEF Capital and the Dementia Discovery FundCAMBRIDGE, Mass.--(BUSINESS WIRE)--QurAlis Corporation, a biotech company…
- April 23, 2020Nitrome Biosciences Raises $38M Series A Financing to Advance Therapeutics Targeting a Novel Group of Enzymes involved in Age-related DiseasesThe…
- April 15, 2020CAMBRIDGE, Mass., April 15, 2020 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new…
- April 14, 2020BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases,…
- March 24, 2020March 23, 2020 at 8:30 AM EDTSOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC)…
- September 9, 2019SV Health Investors announces the appointment of Christian Jung, PhD as Partner in the Dementia Discovery Fund Former Principal at…
- August 12, 2019Press Release: August 12, 2019 AstronauTx secures £6.5 million investment for new approach to dementia therapeutics A new UK-based biotech…
- October 23, 2018Dementia Discovery Fund launches new research accelerator partnership with the UK Dementia Research Institute at inaugural Annual Forum for Dementia…
- July 19, 2018The Dementia Discovery Fund welcomes Bill Gates’ second investment in Alzheimer’s research. Bill is joining Leonard Lauder, ADDF, the Dolby…
- June 25, 2018Dementia Discovery Fund announces the appointment of Angus Grant PhD as CEODr Grant from Celgene to join DDF in JulyDementia…
- June 25, 2018Includes $60 million new investment from US AARPThe DDF is the world’s largest venture fund focused on a single disease…
- June 19, 2018The Dementia Discovery Fund and Immuneering announce a Research Collaboration to identify novel drug targets and drug candidates for Alzheimer's…
- February 20, 201813 February 2018The DDF welcomes new draft guidance from the FDA that endorses a new approach in Alzheimer’s Disease research…
- January 2, 2018Following last year’s meetings in New York and Cambridge, the DDF are again pleased to be presenting at upcoming Johnson…
- November 16, 2017London, 16 November 2017 - The Dementia Discovery Fund (DDF) today announces an investment from the US National Football League Players…
- July 6, 2017Ness Ziona, Israel June 27, 2017 - Mitoconix Bio Ltd., a biopharmaceutical company focused on therapies for neurological diseases, announced today…
- June 19, 2017Dementia Discovery Fund Annual Update Nine investments made since launch, collaborations established with world-leading academic institutions, scientific strategy prioritised and…
- June 1, 2017CAMBRIDGE, England & CAMBRIDGE, MA. (June 1, 2017) — Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based…
- May 3, 2017Dementia Discovery Fund to Invest $5 Million in Cerevance to Seek New Treatments for Dementia London and Boston, 3 May…
- March 15, 2017London, UK - 15th March 2017 - Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments…
- February 28, 2017LONDON, BOSTON, GREENWICH, 28 February 2017 – The Dementia Discovery Fund (‘DDF’), a venture capital fund focused on discovering and…
- October 21, 2016London, 21 October 2015, The Dementia Discovery Fund (DDF), an innovative new global investment fund to support discovery and development…
- June 3, 2016Gen2 is a start-up drug discovery company seeking to develop drugs that target toxic tau species that cause pathology in…
- January 25, 2016London, 25 January 2016 - The Dementia Discovery Fund (DDF) www.TheDDFund.com, an innovative global investment fund launched in October 2015 to…
- January 7, 2016First investment of Dementia Discovery Fund is in pioneering immuno-modulatory antibody discovery company, Alector LLCAlector LLC is developing antibody drugs…
